The FDA approved a new non-opioid painkiller. Its maker's stock is …

3 days ago · “With the approval of Journavax, a non-opioid, pain signal inhibitor and the first new class of pain medicine approved in more than 20 years, we have the opportunity to change the …

CouponFollow Extension

$866
OFF

Vertex Pharmaceuticals Stock Rises As FDA Approves Its Pain Pill

3 weeks from now

3 days ago · The FDA approved a new non-opioid painkiller. Its maker's stock is rising Journavx could bring in as much as $866 million in sales next year, according to one estimate

qz.com

6%
OFF

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA Approval

3 weeks from now

3 days ago · Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the first new non-opioid painkiller in decades.

wsj.com

6%
OFF

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA …

3 weeks from now

3 days ago · Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the first new non-opioid painkiller in decades. …

yahoo.com

6%
OFF

Biotech Stock Rises After FDA Approves Non-Opioid Painkiller

3 weeks from now

2 days ago · Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug Administration (FDA) approved the biotech's new non …

schaeffersresearch.com

FAQs about The FDA approved a new non-opioid painkiller. Its maker's stock is … Coupon?

Why did Vertex Pharmaceuticals stock rise 8% in off-hours trading?

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the first new non-opioid painkiller in decades. The Food and Drug Administration approved Vertex's suzetrigine to treat moderate to severe acute pain. The drug is set to be sold under the brand name Journavx. ...

How did Vertex Pharmaceuticals stock perform after FDA approval?

VERTEX PHARMACEUTICALS INC. After the announcement of Journavx’s receipt of FDA approval, Vertex saw gains in its stock price, with its shares posting more than a 5% jump on Friday. Its market capitalization, meanwhile, hovered around $119.81 billion in the afternoon. ...

Will FDA approve non-opioid pain treatment?

The FDA just approved its potentially game-changing pain treatment. It’s the first new class of pain treatment approved in more than 20 years, Vertex says. The approval of Vertex’s non-opioid pain treatment is the first new class of pain treatment with the FDA’s blessing in 20 years. Photo: AFP via Getty Images ...

Is journavx a non-opioid painkiller?

The Food and Drug Administration approved Journavx, a non-opioid painkiller that is the first novel pain drug to win approval in more than 20 years. (Vertex Pharmaceuticals) The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. ...

Will a new vertex study lead to FDA approval in chronic pain?

Still, Vertex executives said they plan to move forward with a new, late-stage study of the drug, theorizing that a different trial design could yield better results and pave the way for FDA approval in chronic pain. AP video journalist Mary Conlon contributed to this story from New York. ...

Is Vertex Pharmaceuticals a good stock to buy in 2025?

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. ...